Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TODD E SCHLESINGER

Allopathic & Osteopathic Physicians Dermatology

NPI
1538135280
CMS profile
69562
Location
CHARLESTON, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$447,412.48

443 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 9; records 51–100 of 443 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TODD E SCHLESINGER

NPI 1538135280 · CMS profile ID 69562

Allopathic & Osteopathic Physicians / Dermatology

CHARLESTON, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 9; records 51–100 of 443 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538135280?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TODD E SCHLESINGER, NPI 1538135280, CMS profile ID 69562. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 9; records 51–100 of 443 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538135280?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). TODD E SCHLESINGER, NPI 1538135280, CMS profile ID 69562. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 9; records 51–100 of 443 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538135280?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
TODD E SCHLESINGER, NPI 1538135280, CMS profile ID 69562, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 9; records 51–100 of 443 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1538135280?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

443 matching records · $447,412.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 443 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 443.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Pharmaceuticals, Inc. $1,147.0011/22/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114404721 CMS
Regeneron Pharmaceuticals, Inc. $1,147.0011/22/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114404723 CMS
Regeneron Pharmaceuticals, Inc. $5,735.0011/22/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114404725 CMS
Regeneron Pharmaceuticals, Inc. $1,147.0011/22/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114404727 CMS
Novartis Pharmaceuticals Corporation $18.6611/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087157853 CMS
Incyte Corporation $22.6111/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141211591 CMS
Lilly USA, LLC $1,600.0011/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1155959220 CMS
Galderma Laboratories, L.P. $5,100.0011/19/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145326696 CMS
Regeneron Pharmaceuticals, Inc. $134.3211/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114404713 CMS
Dermavant Sciences, Inc. $24.3111/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127929704 CMS
Janssen Biotech, Inc. $1,700.0011/18/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078624720 CMS
Regeneron Healthcare Solutions, Inc. $7.2311/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114161532 CMS
Regeneron Pharmaceuticals, Inc. $220.9311/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114404711 CMS
Regeneron Pharmaceuticals, Inc. $124.2311/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114404709 CMS
Arcutis Biotherapeutics, Inc. $89.9811/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121077045 CMS
UCB, Inc. $36.0611/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143080738 CMS
Regeneron Healthcare Solutions, Inc. $167.5311/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114161514 CMS
Regeneron Healthcare Solutions, Inc. $70.7111/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114161519 CMS
Regeneron Healthcare Solutions, Inc. $10.5111/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114161523 CMS
Regeneron Healthcare Solutions, Inc. $36.7711/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114161527 CMS
Regeneron Pharmaceuticals, Inc. $308.3311/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114404707 CMS
UCB, Inc. $99.0811/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143080736 CMS
Arcutis Biotherapeutics, Inc. $1,500.0011/10/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121077047 CMS
UCB, Inc. $8.3311/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143080706 CMS
UCB, Inc. $8.3311/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143080708 CMS
UCB, Inc. $8.3311/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143080710 CMS
UCB, Inc. $8.3311/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143080712 CMS
UCB, Inc. $8.3411/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143080714 CMS
UCB, Inc. $8.3411/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143080716 CMS
UCB, Inc. $20.0011/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143080718 CMS
UCB, Inc. $20.0011/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143080720 CMS
UCB, Inc. $20.0011/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143080722 CMS
UCB, Inc. $127.3211/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143080724 CMS
UCB, Inc. $127.3211/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143080726 CMS
UCB, Inc. $127.3211/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143080728 CMS
UCB, Inc. $263.9811/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143080730 CMS
UCB, Inc. $263.9811/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143080732 CMS
UCB, Inc. $263.9911/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143080734 CMS
Lilly USA, LLC $1,200.0011/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1155954106 CMS
Lilly USA, LLC $3,200.0011/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1155956682 CMS
Regeneron Healthcare Solutions, Inc. $155.2211/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114161505 CMS
Regeneron Healthcare Solutions, Inc. $181.6011/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114161510 CMS
Almirall LLC $1,600.0011/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120640888 CMS
Almirall LLC $1,600.0011/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120640892 CMS
Regeneron Healthcare Solutions, Inc. $217.3111/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114161488 CMS
Regeneron Healthcare Solutions, Inc. $5.6911/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114161492 CMS
Regeneron Healthcare Solutions, Inc. $137.1811/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114161497 CMS
Regeneron Healthcare Solutions, Inc. $58.0211/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114161501 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $30.8311/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152209194 CMS
Lilly USA, LLC $19.4211/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135450612 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $197,829.79 287
PY2020 $77,873.73 72
PY2021 $118,849.42 127
PY2022 $198,233.46 254
PY2023 $408,961.28 423
PY2024 $447,412.48 443
PY2025 $420,680.61 440

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,490.91 10
PY2025 Principal investigator $218,592.72 37
PY2024 Principal investigator $358,462.53 47
PY2023 Recipient $522.02 2
PY2023 Principal investigator $581,976.09 77
PY2022 Recipient $20,050.00 4
PY2022 Principal investigator $577,263.69 95
PY2021 Recipient $1,947.39 2
PY2021 Principal investigator $744,850.94 70
PY2020 Recipient $1,879.72 4
PY2020 Principal investigator $730,171.91 103
PY2019 Recipient $6,840.75 4
PY2019 Principal investigator $1,328,013.12 129

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

47 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Biofrontera Inc. $9,570.50 12/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF THE CAROLINAS
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $247.51 12/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF THE CAROLINAS LLC
CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY No dispute reported 06/30/2026 1184270213
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,515.20 12/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF THE CAROLINAS
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184274464
Principal investigator 1 ABBVIE INC. $2,858.10 12/04/2025 Non-covered Recipient Entity
CRCC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202526690
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,125.00 11/14/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF THE CAROLINAS
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184261321
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,418.40 11/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF THE CAROLINAS
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190307969
Principal investigator 1 ABBVIE INC. $8,003.57 11/05/2025 Non-covered Recipient Entity
CRCC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202522915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,150.00 10/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF THE CAROLINAS
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184250651
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,463.33 10/10/2025 Non-covered Recipient Entity
Vial Health
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435523
Principal investigator 1 ABBVIE INC. $9,105.87 10/09/2025 Non-covered Recipient Entity
CRCC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202513859
Principal investigator 1 Biofrontera Inc. $7,567.50 09/30/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF THE CAROLINAS
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS No dispute reported 06/30/2026 1208907624
Principal investigator 1 Biofrontera Inc. $7,395.30 09/30/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF THE CAROLINAS
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF SUPERFICIALBASAL CELL CARCINOMA(SBCC) WITH PHOTODYNAMIC THERAPY (PDT). No dispute reported 06/30/2026 1208907629
Principal investigator 1 Galderma Laboratories, L.P. $11,000.00 09/30/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF THE CAROLINAS LLC
A Clinical Study to Assess Efficacy and Tolerability of a Topical Skincare Product on Adults With Mature, Crepey Skin No dispute reported 06/30/2026 1234516876
Principal investigator 1 ABBVIE INC. $20,954.91 09/04/2025 Non-covered Recipient Entity
CRCC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202509590
Principal investigator 1 ABBVIE INC. $3,746.55 08/06/2025 Non-covered Recipient Entity
CRCC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202502915
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $16,334.00 07/23/2025 Non-covered Recipient Entity
Clinical Research Center Of The Carolinas
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235998028
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,206.47 07/17/2025 Non-covered Recipient Entity
Vial Health
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435519
Principal investigator 1 ABBVIE INC. $1,705.80 07/02/2025 Non-covered Recipient Entity
CRCC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202495619
Recipient Regeneron Pharmaceuticals, Inc. $18.20 07/01/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184122235
Recipient Regeneron Pharmaceuticals, Inc. $42.00 07/01/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184122237
Principal investigator 1 Biofrontera Inc. $9.86 06/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF THE CAROLINAS
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF SUPERFICIALBASAL CELL CARCINOMA(SBCC) WITH PHOTODYNAMIC THERAPY (PDT). No dispute reported 06/30/2026 1208907492
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,198.00 06/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF THE CAROLINAS
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184209159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,342.00 06/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF THE CAROLINAS
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184209161
Recipient Regeneron Pharmaceuticals, Inc. $51.86 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184122221
Recipient Regeneron Pharmaceuticals, Inc. $57.46 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184122223
Recipient Regeneron Pharmaceuticals, Inc. $98.90 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184122225
Recipient Regeneron Pharmaceuticals, Inc. $103.02 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184122227
Recipient Regeneron Pharmaceuticals, Inc. $127.07 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184122229
Recipient Regeneron Pharmaceuticals, Inc. $351.03 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184122231
Recipient Regeneron Pharmaceuticals, Inc. $418.88 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184122233
Principal investigator 1 ABBVIE INC. $2,040.75 06/03/2025 Non-covered Recipient Entity
CRCC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202489377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $625.00 05/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF THE CAROLINAS LLC
CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY No dispute reported 06/30/2026 1184193687
Principal investigator 1 ABBVIE INC. $5,095.80 05/07/2025 Non-covered Recipient Entity
CRCC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202483161
Recipient Regeneron Pharmaceuticals, Inc. $222.49 04/30/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184122219
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,103.24 04/14/2025 Non-covered Recipient Entity
Vial Health
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435515
Principal investigator 1 ABBVIE INC. $1,429.05 04/03/2025 Non-covered Recipient Entity
CRCC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202470865
Principal investigator 1 ABBVIE INC. $2,943.96 03/07/2025 Non-covered Recipient Entity
CRCC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202460463
Principal investigator 1 SANOFI US SERVICES INC. $9,600.00 03/04/2025 Non-covered Recipient Entity
Clinical Research Center Of The Carolinas
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226089575
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,558.00 02/21/2025 Non-covered Recipient Entity
CRCC LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223275475
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 02/21/2025 Non-covered Recipient Entity
CRCC LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223275477
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 02/21/2025 Non-covered Recipient Entity
CRCC LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223275479
Principal investigator 1 Biofrontera Inc. $14,541.50 02/14/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF THE CAROLINAS
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907296
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,206.47 02/07/2025 Non-covered Recipient Entity
Vial Health
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435511
Principal investigator 1 ABBVIE INC. $4,578.81 02/06/2025 Non-covered Recipient Entity
CRCC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202447305
Principal investigator 1 Novartis Pharmaceuticals Corporation $34,689.62 02/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF THE CAROLINAS
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190307971
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,962.65 01/17/2025 Non-covered Recipient Entity
Clinical Research Center Of The Carolinas
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235998030
Principal investigator 1 Biofrontera Inc. $2,800.00 01/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF THE CAROLINAS
A NON-RANODMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF BF-200 ALA (AMELUZ) AND BF-RHODOLED XL IN THE EXPANDED FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS ON THE FACE AND SCALP WITH PHOTODYNAMIC THERAPY (PDT) No dispute reported 06/30/2026 1208907261